Capricor Therapeutics Inc: Granted Subsequent Type-B Clinical Meeting With FDA in Q2 to Continue to Discuss Pathway to Bla
Capricor Therapeutics Inc:批准隨後在第二季度與美國食品藥品管理局舉行B型臨床會議,繼續討論通往Bla的途徑
Capricor Therapeutics Inc: Granted Subsequent Type-B Clinical Meeting With FDA in Q2 to Continue to Discuss Pathway to Bla
Capricor Therapeutics Inc:批准隨後在第二季度與美國食品藥品管理局舉行B型臨床會議,繼續討論通往Bla的途徑
使用瀏覽器的分享功能,分享給你的好友吧